Oncotelic Joins Chopra Foundation and Heart Foundation of India to Provide Relief for India's Explosive 2nd Wave of Covid.
04. Mai 2021 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, California, May 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic"), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
ONCOTELIC THERAPEUTICS, INC. ANNOUNCES PRESENTATION AT AYURVEDIC PERSPECTIVES ON COVID-19.
31. März 2021 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Chopra...
MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS
01. März 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH INDIA’S FIRST COMBINED LUNG THERAPY AND AI TELEMEDICINE 360° SOLUTION TO TRANSFORM RESPIRATORY WELLNESS AT WWW.PULMOHEAL.COM
22. Februar 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA™
16. Februar 2021 09:52 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
MATEON LAUNCHES ITS AI TELEMEDICINE PLATFORM FOR POST MARKETING SURVEY TO SUPPORT ITS DRUG PRODUCT FOR INDIA, PULMOHEAL™
01. Februar 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...